Blood clots are the cause of a wide variety of (and often fatal) diseases. Of course, there are drugs for the therapy of thrombus formation, but with constant use they have one very unpleasant property: the development of bleeding. A vaccine developed by scientists from Osaka University (Japan) can come to the rescue. The vaccine can act not only as a prophylaxis for the development of diseases, but also as a means to protect against relapses of diseases already transferred.
The new vaccine so far has the working name S100A9 and has already undergone a series of successful experiments in mice. It was found to provide protection against blood clots for more than two months from the date of placement. In addition, the vaccine does not induce autoimmune reactions and does not increase the risk of bleeding. Such a long period of action is truly a real breakthrough. According to one of the study authors, Dr. Hironori Nakagami, In experiments, the S100A9 vaccine was compared with one of the most widely used drugs for preventing blood clots, clopidogrel. It turned out that the vaccine has the same effectiveness of action as the anticoagulant. But scientists themselves are cautious about the future of their development.
Vladimir Kuznetsov
